Tests SGR-1505 in adults with B-cell lymphoma and related blood cancers
Tests the drug SGR-1505 for safety in adults with B-cell blood cancers.
Plain-language title generated from the registry record
Registry title: Study of SGR-1505 in Mature B-Cell Neoplasms
Key facts
- Where
- L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón, and Salamanca, SpainSee the 7 sites
- Phase
- Phase 1
Where in Spain
- Institut Catala D'oncologiaL'Hospitalet de Llobregat, SpainTaking people
- Clinica Universidad de NavarraMadrid, SpainTaking people
- Hospital Universitario Fundación Jiménez DíazMadrid, SpainTaking people
- Hospital Universitario HM SanchinarroMadrid, SpainTaking people
- Clínica Universidad de navarraPamplona, SpainTaking people
- Hospital Universitario Quironsalud MadridPozuelo de Alarcón, SpainTaking people
- Hospital Universitario De SalamancaSalamanca, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Schrödinger, Inc.
- Trial code
- NCT05544019EU 2023-505204-34-00
- Record updated
- 13 February 2026
- Original description
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.Read full original descriptionShow less
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Inclusion: Subject must have a history of histologically or cytologically confirmed mature B-cell malignancy; Subject must have measurable or detectable disease according to the applicable disease-specific classification system and meet criteria for initiation of treatment; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Life expectancy ≥ 12 weeks.
Exclusion: The subject is in need of immediate cytoreductive therapy (unless the patient has no remaining treatment choice with potential benefit); Subject has previous invasive malignancy in the last 2 years; Subject has a known allergy to SGR-1505 or excipients of SGR-1505; Subject has symptomatic or active CNS involvement of disease; Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that would place the participant at increased risk to the use of an investigational drug.